BG63122B1 - Compounds and methods for cancer treatment - Google Patents

Compounds and methods for cancer treatment

Info

Publication number
BG63122B1
BG63122B1 BG101284A BG10128497A BG63122B1 BG 63122 B1 BG63122 B1 BG 63122B1 BG 101284 A BG101284 A BG 101284A BG 10128497 A BG10128497 A BG 10128497A BG 63122 B1 BG63122 B1 BG 63122B1
Authority
BG
Bulgaria
Prior art keywords
compounds
methods
cancer treatment
treatment
citosyne
Prior art date
Application number
BG101284A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101284A (en
Inventor
Chung Chu
Yung-Chi Cheng
Original Assignee
Yale University
University Of Georgia Research Foundation,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Yale University, University Of Georgia Research Foundation,Inc. filed Critical Yale University
Publication of BG101284A publication Critical patent/BG101284A/xx
Publication of BG63122B1 publication Critical patent/BG63122B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
BG101284A 1994-09-06 1997-03-05 Compounds and methods for cancer treatment BG63122B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
BG101284A BG101284A (en) 1998-03-31
BG63122B1 true BG63122B1 (en) 2001-04-30

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101284A BG63122B1 (en) 1994-09-06 1997-03-05 Compounds and methods for cancer treatment

Country Status (31)

Country Link
US (3) US6063787A (ja)
EP (2) EP1468687A1 (ja)
JP (1) JP3979662B2 (ja)
KR (1) KR100374477B1 (ja)
CN (3) CN1827108A (ja)
AP (1) AP783A (ja)
AT (1) ATE267015T1 (ja)
AU (1) AU704977B2 (ja)
BG (1) BG63122B1 (ja)
BR (1) BR9508886A (ja)
CA (1) CA2199117C (ja)
CZ (1) CZ297873B6 (ja)
DE (1) DE69533066T2 (ja)
DK (1) DK0781136T3 (ja)
ES (1) ES2219666T3 (ja)
FI (1) FI970918A (ja)
HU (1) HUT77172A (ja)
IL (1) IL115156A (ja)
IS (1) IS2011B (ja)
MY (1) MY121548A (ja)
NO (1) NO313268B1 (ja)
NZ (1) NZ335013A (ja)
OA (1) OA10473A (ja)
PL (2) PL189288B1 (ja)
PT (1) PT781136E (ja)
RO (1) RO118748B1 (ja)
RU (1) RU2168995C2 (ja)
SI (1) SI0781136T1 (ja)
SK (1) SK284564B6 (ja)
WO (1) WO1996007413A1 (ja)
ZA (1) ZA957483B (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
JP2001512830A (ja) 1997-08-08 2001-08-28 ニューバイオティックス インコーポレイテッド 生物療法耐性および化学療法耐性を克服するための方法および組成物
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
IL137164A0 (en) 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
ES2276515T3 (es) 1998-02-25 2007-06-16 Emory University 2'-fluoronucleosidos.
ATE442151T1 (de) 1999-03-29 2009-09-15 Shire Canada Inc Verwendung von cytidinderivaten zur behandlung von leukämie
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
EP1214074B1 (en) 1999-09-24 2004-06-16 Shire Biochem Inc. Dioxolane nucleoside analogs for the treatment or prevention of viral infection
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
CA2425359A1 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
AU2002241911B9 (en) 2001-01-19 2007-01-25 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
NZ528394A (en) 2001-03-23 2005-06-24 Shire Biochem Inc Pharmaceutical combinations for the treatment of cancer comprising dioxolane analogues and nuceloside analogues and/or chemotherapeutic agents
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
US20030027799A1 (en) * 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
EP1441733A1 (en) * 2001-11-02 2004-08-04 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
MXPA04004532A (es) * 2001-11-19 2004-08-11 Medigene Ag Medicamento para el tratamiento de enfermedades tumorales y virales de la piel.
MXPA04002365A (es) 2002-06-21 2004-11-22 Lg Electronics Inc Medio de grabacion que tiene estructura de datos para manejar la reproduccion de datos de video grabados en el mismo.
AU2003228113B2 (en) 2002-06-21 2009-02-26 Lg Electronics Inc. Recording medium having data structure for managing reproduction of video data recorded thereon
JP4418747B2 (ja) 2002-06-24 2010-02-24 エルジー エレクトロニクス インコーポレイティド ビデオデータの再生を管理するためのナビゲーション制御情報が含まれたデータ構造を有する記録媒体と、それによる記録と再生の方法及び装置
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
WO2004003908A1 (en) 2002-06-28 2004-01-08 Lg Electronics Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
JP4431043B2 (ja) 2002-10-14 2010-03-10 エルジー エレクトロニクス インコーポレイティド 記録された複数のオーディオストリームの再生を管理するためのデータ構造を有する光ディスク、それによる記録及び再生方法及び装置
ATE547792T1 (de) 2002-10-15 2012-03-15 Lg Electronics Inc Aufzeichnungsmedium mit einer datenstruktur zur verwaltung der wiedergabe mehrerer darauf aufgezeichneter grafikströme und aufzeichnungs- und wiedergabeverfahren und vorrichtungen
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
WO2004077417A1 (en) 2003-02-28 2004-09-10 Lg Electronics Inc. Recording medium having data structure for managing random/shuffle reproduction of video data recorded thereon and recording and reproducing methods and apparatuses
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
WO2005037300A1 (en) 2003-10-09 2005-04-28 Medigene Ag The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
BRPI0613796A2 (pt) * 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
US7951788B2 (en) * 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
CA2662147A1 (en) * 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. L-oddc prodrugs for cancer
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
JP7110203B2 (ja) * 2016-12-28 2022-08-01 トランジェーヌ 腫瘍溶解性ウイルスおよび治療用分子
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
ATE190064T1 (de) * 1985-09-17 2000-03-15 Wellcome Found Kombination therapeutische nukleoside mit weiteren therapeutisch wirksamen komponenten.
IN164556B (ja) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
AU613026B2 (en) * 1987-03-24 1991-07-25 Nycomed As 2',3' dideoxyribofuranoxide derivatives
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
DE68922903T2 (de) * 1988-12-19 1995-11-23 Wellcome Found Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
DE69233693T2 (de) * 1991-03-06 2008-01-24 Emory University Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
AU1596495A (en) * 1993-12-30 1995-07-17 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
HUT77172A (hu) 1998-03-02
IL115156A0 (en) 1995-12-31
CN1111409C (zh) 2003-06-18
RO118748B1 (ro) 2003-10-30
CZ297873B6 (cs) 2007-04-18
DK0781136T3 (da) 2004-08-02
SI0781136T1 (en) 2004-08-31
BG101284A (en) 1998-03-31
CN1448142A (zh) 2003-10-15
CZ63397A3 (en) 1997-07-16
FI970918A0 (fi) 1997-03-04
OA10473A (en) 2002-04-08
ES2219666T3 (es) 2004-12-01
SK284564B6 (sk) 2005-06-02
AU3586295A (en) 1996-03-27
ATE267015T1 (de) 2004-06-15
EP0781136B1 (en) 2004-05-19
FI970918A (fi) 1997-05-02
KR100374477B1 (ko) 2003-06-19
BR9508886A (pt) 1997-12-30
NO971015D0 (no) 1997-03-05
NO313268B1 (no) 2002-09-09
IS4434A (is) 1997-03-04
IL115156A (en) 2000-07-16
PL188359B1 (pl) 2005-01-31
CN1827108A (zh) 2006-09-06
US8076347B2 (en) 2011-12-13
PT781136E (pt) 2004-09-30
DE69533066T2 (de) 2005-06-02
US20080171758A1 (en) 2008-07-17
SK28197A3 (en) 1997-09-10
EP1468687A1 (en) 2004-10-20
NO971015L (no) 1997-03-05
MY121548A (en) 2006-02-28
IS2011B (is) 2005-05-13
CN1251680C (zh) 2006-04-19
DE69533066D1 (de) 2004-06-24
EP0781136A4 (en) 1999-06-23
EP0781136A1 (en) 1997-07-02
RU2168995C2 (ru) 2001-06-20
JPH10506385A (ja) 1998-06-23
KR970705393A (ko) 1997-10-09
US20050261320A1 (en) 2005-11-24
AP9700939A0 (en) 1997-04-30
PL189288B1 (pl) 2005-07-29
CA2199117A1 (en) 1996-03-14
ZA957483B (en) 1997-06-06
JP3979662B2 (ja) 2007-09-19
US6063787A (en) 2000-05-16
NZ335013A (en) 2000-07-28
PL318971A1 (en) 1997-07-21
CA2199117C (en) 2006-04-11
AP783A (en) 1999-11-17
WO1996007413A1 (en) 1996-03-14
AU704977B2 (en) 1999-05-13
CN1160351A (zh) 1997-09-24
US7262213B2 (en) 2007-08-28

Similar Documents

Publication Publication Date Title
BG63122B1 (en) Compounds and methods for cancer treatment
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
IL125223A0 (en) Novel substituted imidazole compounds
PL327934A1 (en) Novel substituted imidazole compounds
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
DE59914996D1 (en) Heterocyclisch substituierte amide als calpainhemmer
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MX9705296A (es) Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
BG105270A (en) Tetrahydropyridoethers
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
MX9700557A (es) Dihidrobenzofuranos.
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
HK1040983A1 (en) Quinones for treatment of diseases.
ATE169445T1 (de) Verwendung von gelformulierungen als beizmittel
MX9707022A (es) Derivados de fenilo trisustituidos.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
SE9802937D0 (sv) Novel compounds
AU3474699A (en) Novel retinoids and use thereof
BG101126A (en) The use of muramylpeptide compounds
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MX9700624A (es) Azolidinonas de imidazopiridina.
YU58600A (sh) Oblik vi 5,6-dihloro-2-(izopropilamino)-1-(beta-l-ribofuranozil)-1h-benzimidazola
DE69835828D1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
HK1048263A1 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides.
KR0177821B1 (en) Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans